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Targeted therapies (TTs) have revolutionised cancer treatment with their enhanced specificity of 
action. Compared with conventional therapies, TTs are delivered over a longer period and often 
have unusual symptom profiles. Patient reported outcome measures such as symptom side-effect 
lists need to be developed in a time-efficient manner to enable a rapid and full evaluation of new 
treatments and effective clinical management 
Objective 
The aim of this study is to develop a set of TT-related symptoms and identify the optimal method for 
developing symptom lists.  
Patients and Methods 
Symptoms from TT treatment in the context of Chronic Myeloid Leukaemia (CML), HER2 positive 
breast cancer, or Gastrointestinal Stromal Tumours (GIST) were identified through literature reviews, 
interviews with health care professionals (HCPs) and patients, and patient focus groups. The 
symptom set was then pilot tested in patients across the three cancer diagnoses: The number of 




A total of 316 patients and 86 HCPs from 16 countries participated. An initial set of 209 symptoms 
was reduced to 61 covering 12 symptom categories. Patient interviews made the greatest 
contribution to the item set. 
Conclusions 
Symptom lists should be created based on input from patients. The item set described will be 
applicable to the assessment of new TTs, and in monitoring treatment. 
 
Key Points 
Development of symptom measures needs to be rapid to respond to the ever-changing treatment 
landscape. 
Symptom sets are a resource to create symptom lists in a time-efficient manner. 
The content of symptom lists should be informed by patient experience. 
 
 
1. Introduction     
Patient reported outcome (PRO) measures provide an assessment of a patient’s health condition 
from the patient’s perspective rather than relying on the interpretation of others, such as clinicians 
(1). In recent years there has been increased focus on PROs in clinical trials, clinical practice, and 
health technology assessments (2-5). The Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) recommend the use of PRO measures in marketing applications for new 
treatments (2, 4) and place emphasis on patient-reported symptoms. Symptom assessment 
enhances precision in describing the patient’s symptom experience as well as monitoring treatment 
side-effect profiles (6). Online symptom reporting by patients with cancer can facilitate 
comprehensive symptom capture in real time, reduce costs and allow for timely detection and 
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management of symptoms (7-9). This can translate into improved patient experience and outcome 
(10). The National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) 
enables patients to report symptoms related to cancer and its treatment directly onto a trial 
database (11). Others have used a more flexible computer-adaptive testing approach to tailor 
symptom assessment according to patient relevance, and thus reduce respondent burden (12, 13). 
All these systems require the identification and/or construction of many items which can be labour-
intensive and costly.  
 
Cancer- and treatment-related symptoms have a significant impact on health-related quality of life 
(HRQOL) and form an integral part of its definition and assessment. Symptom items feature strongly 
in HRQOL assessments. For example, 17 of 30 items in the widely used EORTC Quality of Life core 
cancer questionnaire, the EORTC QLQ-C30, refer to symptoms. However, symptom lists alone do not 
provide a full assessment of HRQOL,  which includes the broader domains of physical, role, cognitive, 
emotional, and social functioning (14).   
 
Targeted therapies (TTs) have revolutionised treatments of several cancers especially HER2 positive 
breast cancer (trastuzumab) (15) , haematological malignancy such as Chronic Myeloid Leukaemia 
(CML) (16) , and Gastro Intestinal Stromal Tumours (GISTs) (imatinib) (17, 18), by substantially 
improving clinical outcomes since their approval towards the end of the last century and the early 
2000s. TTs selectively target molecular agents involved in tumour growth and progression. Despite 
their selectivity, TTs cause a range of unexpected and unpredictable symptoms, such as rash and 
headache, rarely seen with traditional treatment. In our review of the literature on the side-effects 
of TTs used for GISTS, skin-related problems, particularly Hand-Foot syndrome associated with 
sunitinib, were reported in nearly half of the papers reviewed affecting  37% of patients in the 
randomised clinical trials and case reports reviewed (19). Furthermore, TTs are delivered for much 
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longer than standard chemotherapy, with a longer exposure to potential side-effects. With long-
term drug administration, low-grade side-effects may significantly interfere with patients’ wellbeing 
and daily functioning and may be overlooked (20, 21). These unusual symptoms are likely to go 
undetected by HRQOL questionnaires developed before the widespread use of TTs.  
In addition to the EORTC Quality of Life core cancer questionnaire, the EORTC Quality of Life Group 
(QLG) has developed a suite of questionnaires specific to different tumour or condition types using a 
rigorous and time-consuming process (22). A more flexible and dynamic approach has been 
proposed which recognises the need to keep pace with the ever-changing treatment landscape and 
includes symptom side-effect questions as an add-on to EORTC measures. (6). This strategy is 
facilitated by the EORTC QLG Item Library which includes nearly 1000 validated, multi-lingual items 
from the EORTC questionnaires (23, 24). Recent studies adopting this flexible approach include 
routine electronic monitoring of HRQOL in metastatic renal cell cancer, which used the EORTC QLQ-
C30 with nine questions from the Item Library to assess common treatment-related symptoms (25) 
and a study of rare cancers in which 10 items were selected from the Item Library to supplement the 
EORTC QLQ-C30 (26).   
The aim of the current study was to identify a symptom set for patients treated with TTs using the 
EORTC QLG Module Guidelines (22) and to use this process to inform recommendations for the 
optimal method for developing symptom lists across different patient groups.   
2. Methods 
The development process covered three phases: Phase 1: identification of symptoms to include in 
the item set, from systematic reviews of the literature, interviews with patients and health care 
professionals (HCPs) with experience of TTs and patient focus groups; Phase 2: selection of 
symptoms and creation of the item set; Phase 3: Pilot testing the item set in patients to ensure 
7 
 
acceptability, comprehension and completeness of the set. Interviews were conducted in several 
countries and languages to ensure multi-cultural relevance.   
2.1 Tumour types and targeted therapies 
We recruited patients treated (either currently or previously) with TT for either CML, HER2 positive 
breast cancer, or GIST, cancer types in which TTs featured prominently within their treatment at the 
time of writing the protocol for this study. Given that different TTs are used to treat these cancers, it 
was anticipated that we would capture a broad range of symptoms. In addition, these cancer 
scenarios were chosen for pragmatic reasons with each one having a different starting point for the 
generation of the item set, explained below.  
CML is a common haematological malignancy and TTs are now widely used in its treatment.  Indeed, 
these therapies have remarkably improved survival of patients with CML (27). When the present 
study began, there was an EORTC CML-specific questionnaire in development (EORTC QLQ-CML24) 
(28). We therefore used the symptom data collected as part of that work (28) to inform the 
development of the item set. 
Breast cancer is a common cancer, and was one of the first to benefit from TTs with the introduction 
of trastuzumab (29, 30). The development of the EORTC breast cancer module (EORTC QLQ-BR23) 
(31) was completed in 1996 before the advent of TTs.  
GIST is a rare cancer which also responds well to TTs. Historically, in the context of advanced or 
unresectable GISTS, treatment options were limited. TTs such as imatinib have become the standard 
therapy (31), There is currently no GIST-specific EORTC module to assess the impact of GIST and its 
treatment on HRQOL . 
2.2 Scope of the Item Set 
We adapted a dictionary definition of symptoms for the purpose of this study (32). Symptoms 
eligible for inclusion in the item set were defined as those described by patients as a “physical or 
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psychological disturbance from normal biological function, sensation or appearance (but not the 
impact or interference with normal activities arising from such disturbances, such as activity 
limitations, or body image)”. In this study our focus was on symptoms which are a consequence of 
treatment, rather than a marker of the disease itself, although we acknowledge that the distinction 
between treatment-related and disease-related symptoms is not always clearly delineated. 
Medically defined changes such as abnormal blood tests or a diagnosis based on clinical investigation 
rather than patient experience were excluded.   
Although only the three disease scenarios mentioned above were included in the development of 
the item set, the intention was for the item set to be used and adapted for different cancer and TT 
types. 
2.3 Phase 1  
2.3.1 Literature reviews  
Systematic reviews of the literature relating to toxicities of TTs for CML, breast cancer, and GIST 
have been reported elsewhere (19, 33, 34). 
2.3.2 Patient interviews and focus groups   
In the development of the QLQ-CML24, patients with CML were interviewed and asked to rate the 
relevance and importance of HRQOL concerns (including symptom issues) captured from the 
literature. Full details are reported elsewhere (28).  
Interviews were conducted with patients diagnosed with HER2 positive breast cancer or GIST. The 
numbers of patients interviewed were in accordance with QLG Guidelines (22). Patients who were 
receiving or had previously received TT for breast cancer or GIST were invited to participate by their 
clinician. In addition, patients with GIST were recruited for telephone interviews through the GIST UK 
Support Group website.  Finally, a focus group was conducted for each diagnosis in Southampton, 
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UK. The focus groups provided an opportunity for patients to collectively review the set of 
symptoms captured thus far and to consider new symptoms. 
In a semi-structured interview, or focus group, patients were asked to consider their experiences 
while taking TT and to only report, where possible, side-effects they associated with TTs, rather than 
the cancer itself, other treatments, or other factors such as pre-existing conditions and age.   
The interview and focus group schedules are presented as supplementary material (Supplementary 
material 1). 
2.3.3 HCP Interviews 
As part of the development of the EORTC QLQ-CML24, interviews were conducted with HCPs who 
treat CML (28).   
Interviews with HCPs, with specialist experience in breast cancer or GIST were also carried out at 
each participating centre.  The interviews were carried out in parallel with the patient interviews. 
HCPs were asked to report side-effects they associated with TTs.  
2.4 Phase 2 
2.4.1 Selection of symptoms  
The researchers reviewed all symptoms generated from the interviews, focus groups and literature 
reviews. Symptoms generated by more than one data capture method (literature, interviews 
(patients and HCPs) or focus groups), and those with a prevalence of at least 5% of interviews were 
considered for retention. Symptoms with closely related content were rejected or combined to 
avoid redundancy.   
2.4.2 Item generation 
Questions included in existing EORTC quality of life questionnaires were firstly reviewed to identify 
whether they offered a good match to the symptoms identified. The wording of existing EORTC 
questions was sometimes adapted to adequately cover the symptom under consideration. When 
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there was no corresponding item, new symptom questions were constructed. A time frame of “the 
last week” for recall of symptoms was chosen, for consistency with the usual time frame of validated 
EORTC items although, for some symptoms, where little change would be expected over a week, the 
time frame of “the past 4 weeks” was adopted . 
2.4.3 Clinical review and translation 
The item set for breast and GIST patients was sent to six health professionals in the participating 
centres. Reviewers were asked to consider whether the items were relevant and appropriate for 
their patients and to consider any important omissions.  The CML items also underwent clinical 
review and translation as part of the development of the EORTC QLQ-CML24.  
2.5 Phase 3: Pilot testing the item set 
A draft item set was pilot tested with a separate group of patients diagnosed with CML, breast 
cancer, or GIST, and who were receiving or had previously been treated with TT. Patients were asked 
to complete the EORTC QLQ-C30 and the draft item set, and to rate the incidence, relevance and 
importance of each symptom from “not at all” to “very much”. They were also asked to identify any 
important omissions from the set and whether any items were upsetting or inappropriate, or 
difficult to understand. Items reported as confusing, and those displaying overlap with other items 
were considered for rejection.  
2.5.1 Generation of recommendations for developing item sets 
In order to evaluate the contribution of each method of symptom capture (literature, patients and 
HCPs) to the provisional and final item set, the number of symptoms captured by each method was 
compared. This comparison informed recommendations for the optimal practice of generating 




All procedures were in accordance with the ethical standards of the institutional and/or national 
research committee and with the 1964 Helsinki Declaration and its later amendments or comparable 
ethical standards. The study was approved at the lead site (University of Southampton, United 
Kingdom) by NRES Committee South Central Southampton B (11/SC/0412).  All patients gave 
informed written consent to participate.  
3 Results 
3.1 Phase 1 
3.1.1 Literature reviews 
Of the 74 HRQOL issues identified from the CML literature review (34), 45 described symptoms. 
Forty-one issues were identified from the physical symptom category list (such as swelling, cramps 
and gastro-intestinal symptoms) and four from the psychosocial category (such as depression and 
worry).   
The breast cancer literature review identified a total of 46 symptoms (33). Diarrhoea and skin rash 
were the most prevalent symptoms, experienced by 29% and 22% of patients overall.  Most 
symptoms (n = 52) were experienced by 1% or less of patients and were predominantly of Grade 1/2 
toxicity. 
Our review (19) of symptoms experienced during treatment with TTs for GIST identified 64 
symptoms covering physical side-effects such as fatigue, nausea, and oedema, as well as 
psychological symptoms of depression, confusion and concentration problems. Fifty-six (88%) 
symptoms were captured from studies reporting side-effects of imatinib and 33 (52%) related to 
sunitinib. Important differences in the symptom profiles of imatinib and sunitinib were seen in the 
frequencies of oedema, muscle and joint pains, skin and oral conditions.  
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3.1.2 Interviews and focus groups 
3.1.2.1 Patients  
Interviews were conducted with 137 patients receiving treatment for CML (mean age of 56.7 years) 
in seven hospitals in Germany, Greece, Italy, Iraq and Taiwan (28). Forty-three percent of patients 
were on treatment with first line imatinib and 46% were on second-line treatment with second 
generation TKIs (nilotinib and then dasatinib). About half of the patients (53%) had been treated for 
more than five years. An additional 99 patients were recruited through an Italian CML patient 
advocacy website and invited to comment on the HRQOL issues.  Data generated from this sample 
were used for supportive analysis.  
Fifty-three female patients with breast cancer, 47 of whom were currently receiving TT (s) were 
interviewed across five countries and an additional 5 patients attended a focus group (Table 1). 
Twenty-seven patients from three countries currently on TT for a GIST were interviewed and a 
further 5 patients attended a focus group (Table 1).  
Table 2 outlines the clinical characteristics (including type of TT) of the patients with breast cancer 
and GIST.  
3.1.2.2 Health Care Professionals  
Fifty-nine HCPS from 12 countries treating patients with CML were interviewed as part of the EORTC 
QLQ-CML24 development (28). Twenty-five HCPs with expertise in treating breast cancer or GIST 
were also interviewed (Table 3).  
3.1.3 Symptoms  
Forty-five CML-related symptoms were identified in the development of the EORTC QLQ-CML24; 112 
symptoms were reported by patients with breast cancer, and 141 by those with GIST.  
In the HCP interviews, a total of 72 symptoms were identified for breast cancer and 53 symptoms 
were identified for GIST.  
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Patients described 209 symptoms (Table 4). Of these, 61 were reported within the context of breast 
cancer, 77 in GIST and 70 in both tumour types. One additional symptom (problems with sweating) 
was obtained from the CML data (Table 5).  
3.1.4 Contribution of each method to the development of the item list 
 
Forty-seven symptoms in the draft list were captured by all sources (literature, patients and HCPs). 
Each source of symptoms gave some unique issues (Table 4) with patients offering the greatest 
contribution of these: the literature and HCPs identified one unique symptom each (Infections was 
uniquely captured in the literature and bleeding gums mentioned only by HCPs) while patient 
interviews identified six unique symptoms (frequent urination, feeling tense, heart palpitations, 
pale/cold fingers, impaired motivation and sensitivity of the skin to the sun). In addition to infections 
and bleeding gums, only two other symptoms (painful bowel movements and cough) were not 
mentioned by patients. 
3.2 Phase 2 
3.2.1 Selection of symptoms 
Figure 1 outlines the process of reduction of symptoms into the draft item set. This included 74 
symptoms, organised in 15 categories (Table 4). With the exception of infection, weight gain and 
weight loss, which were rated “during the past 4 weeks”, all symptoms were scored “during the past 
week”.  
3.3 Phase 3 
3.3.1 Pilot testing the draft item set 
One hundred and two patients from seven countries completed the draft item set (Supplementary 
material 2; Table 2.1). Just over half the sample (51%) had breast cancer, followed by GIST (34%) and 
CML (15%). Patients had experience of treatment with at least one of 10 TTs (Supplementary 
material 2; Table 2.2), the most common TT was imatinib (41%) followed by trastuzumab (38%), and 
14 
 
32% started TT in the last 6 months. Except for two patients, all respondents were currently 
receiving treatment. 
The prevalence of symptoms across all three cancer types and different TTs was low. For 29 
symptoms, fewer than 10% patients rated their severity “quite a bit” or “very much”. The two most 
frequently reported symptoms were lack of energy (45%) and tiredness (42%). These symptoms 
were recognised as relevant and important by over two-thirds of patients (68% and 69% 
respectively). 
After a review of patient comments, 13 items were removed, and some adjustments were made to 
the categories (Table 4). No new symptoms were identified. The remaining 61 items are presented in 
Table 5 with the disease scenario in which they were reported during Phase 1 interviews, focus 
groups and literature reviews. Table 5 shows the distribution of symptoms across cancer types; 
some symptoms were unique to one cancer, for example, heart palpitations and breast cancer 
(trastuzumab) and red (bloodshot) eyes and GIST (imatinib). The symptoms are organised within 
categories for convenience, but this does not imply that there is a scale structure.   
Eight symptoms (skin rash, sore or painful skin, palpitations, dry eyes, itchy eyes, nose bleeds, other 
nose problems, dizziness) were not identified within the EORTC QLG Item Library and represent new 
items and 15 (e.g., skin colour changes, itchy skin, watery eyes) required adaptations of existing 
EORTC QLG items.   
3.3.2 Contribution of each method to the development of the final item set 
Patients made the greatest contribution to the final symptom set with 58 of the 61 symptoms 
mentioned by patients during Phase 1 interviews and focus groups, compared with 47 presented by 




This paper describes the process of identifying and creating a set of symptoms experienced by 
patients with three different cancers treated with a range of TTs. The well-established QLG methods 
(22) for item generation were used. Comparison of the source(s) of each item has enabled the 
formulation of recommendations for developing and using item lists for specific TTs and tumour 
sites.  
4.1 Creating Item Lists 
In line with the robust EORTC QLG recommendations for questionnaire generation (22), three 
sources were used to identify potential symptoms for inclusion in the item set and we were able to 
compare the input from each source. Data were retrieved from interviews with patients and HCPs, 
patient focus groups and systematic reviews of the literature. Literature reviews were time-
consuming and labour-intensive. None of the symptoms identified only from the literature reviews 
were included in the final item set. To identify side-effects of new treatments during development, a 
full systematic review is unlikely to be productive. 
Patients’ accounts of symptoms offered the greatest contribution to the content of the item set and 
we therefore recommend, as a minimum, involving patients in the development of symptom lists. 
Our recommendation to prioritise patient interviews in the development of symptom lists will 
ensure content validity as well as reduce the resource burden on the development process. This 
mirrors other work underlining the importance of the patient’s voice in the identification of 
symptoms to be included in PRO measures (26).  
During product development, patient experience with a new drug may be limited. The greatest 
amount of patient-reported data on symptoms associated with a new treatment is likely to be in the 
case report forms from phase 1 and 2 clinical trials. We recommend consulting these data when an 
item list is created to be used in a phase 3 clinical trial.  
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The EORTC QLG Item Library is a valuable resource when creating item lists (23). It consists of items 
that have been developed with care to avoid confusing phrasing, and to facilitate translation; the 
items have all been widely tested and found to be acceptable in a variety of cultures, and all items 
have already been translated into many languages. Most items (87%) included in our item set were 
obtained from the EORTC QLG Item Library, although a small number required slight modification. 
For eight symptoms not covered by existing items, new questions were developed using a format 
consistent with existing items. These have now been added to the Item Library. All items included in 
the set, including the newly created ones, were acceptable to patients during pilot testing which 
suggests that this method could be replicated for other conditions or treatments. These items will 
make a valuable contribution to the rapid development of measures to evaluate new treatments 
across different tumour types, consistent with EORTC QLG strategy (5). The EORTC QLG is currently 
developing guidelines to assist researchers design new, perhaps trial-specific, symptom 
questionnaires, during development of new therapies. The symptoms set may also be used to 
monitor treatment with TTs, for example to document the response to changes in therapy. 
4.2 Recommendations for optimising practice for generating item lists 
The following recommendations for developing an item set are proposed:  
1. Identify relevant issues using patient interviews in the target population.  
2. Supplement the interview data with a review of clinical reports and preclinical trial data. 
3. Search the EORTC QLG Item Library for relevant questions. If new items are required, EORTC 
QLG guidance should be followed. 
 
4.3 Using Item Lists 
Current EORTC QLG strategy recommends using additional items from the EORTC QLG Item Library 
as an “add-on” to supplement the EORTC QLQ-C30 and existing disease-specific measures. This 
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strategy aims to enhance sensitivity to the side-effects of new treatments (23, 24) and should 
facilitate the measurement of adverse events of new treatments, and their impact on the common 
functional health problems reported by patients.  
In the context of two of the cancer types investigated in the current study, CML and breast cancer, 
an item list could be used alongside the EORTC QLQ-C30 and the relevant disease-specific module. In 
breast cancer, for example, a clinician or researcher could use the EORTC QLQ-C30 with the newly-
updated EORTC QLQ-BR45 (35), and add the symptom items of broken nails and heart palpitations. 
For GIST, where there is currently no specific module, an item set could be used to record swelling, 
cramps, eye and skin problems, to complement the EORTC QLQ-C30, with the caveat that the item 
set provides data only about treatment-related symptoms rather than GIST-specific functioning. 
In some cases, an investigator may be concerned with comparing specific symptoms associated with 
different treatments, rather than the full symptom profile. The symptom set generated in this study 
is organised into categories to facilitate the generation of focussed symptom lists, for example, to 
assess gastro-intestinal or skin symptoms. 
Item lists could serve as a valuable tool to support clinicians’ consultations with patients, enhancing 
the quality and content of such consultations (36). A set of questions about symptoms could be 
completed before the patient sees the clinician. This will identify symptoms relevant to the patient 
to be discussed during the consultation, supporting the delivery of personalised care.  Showing 
patients symptom lists prior to their consultation could open up conversations about rare and 
unexpected symptoms which might otherwise be overlooked and might serve as an early warning 
system.  Some of the symptoms (e.g., skin colour changes) in the list we generated were not 
mentioned by HCPs perhaps because untreated, they are not likely to have serious health 
implications. However, these symptoms can affect patients’ HRQOL and compliance with treatment. 
HCPs are unlikely to have treatments to overcome these symptoms, yet they remain very relevant to 
patients. Having this information about a list of symptoms that patients believe to be relevant to 
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their well-being is critical to open consultations that meet a patient’s needs and could inform the 
development of symptom control treatments.  
4.4 Caveats 
The item set presented is not intended for use in its entirety; not all symptoms are relevant for all 
disease and treatment scenarios.   
Although the item set generated in this study is extensive in its coverage of symptoms, the set is 
expected to expand to accommodate novel symptoms reported by patients treated with new and 
different TTs.  
It is important to reiterate that item lists do not provide a comprehensive measure of HRQOL. Rather 
they can supplement existing HRQOL measures. 
We do not recommend generating a total score from item lists; each item should be scored 
separately rather than used to create sub-scale scores. 
 
4.5 Strengths of the study 
This study used the rigorous methodology of the EORTC QLG (22) which involved different strategies 
of  generating symptoms related to a variety of TTs used in the treatment of three different cancer 
types. This ensured comprehensive coverage of potential items, and multinational, multilingual 
development. The study design also lent itself to a comparison of the unique contribution of each 
method of symptom-capture: literature, patients and HCPs. 
 
4.6 Limitations of the study 
This study developed an item set that would be useful for symptom reporting by patients receiving 
TTs. For practical considerations the patient groups were limited to three tumour types, and the 
therapies included were those in wide use at the time of the study. Additional symptoms may be 
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experienced with other tumours or new therapies. However, we have offered recommendations for 
the creation of bespoke symptom lists specific to other TT types.  Although at the outset we defined 
the scope of what would be considered a symptom, some issues initially selected for inclusion were 
subsequently rejected as they did not fit the symptom definition, suggesting that there was initial 
lack of clarity in the application of the symptom definition. Finally, symptoms were only selected if 
they were perceived by the patient as specifically TT-induced. The challenge of identifying symptoms 
that are exclusively treatment-related is widely acknowledged (37) and we relied on patient recall of 
onset, and whether dose modification led to an improvement in symptoms. We aimed to be 
inclusive of symptoms rather than rigorous in attributing their cause.  
5. Conclusion 
This study has demonstrated the feasibility of developing a patient-reported assessment of 
symptoms specific to novel TTs using the robust methods recommended by the EORTC QLG. Our 
study underlines the central role of patients in the development of PRO measures including item 
sets. We recommend that investigators and clinicians can select individual symptoms from the Item 
Library to create bespoke symptom assessments to supplement HRQOL assessment.  Such a list 
would include symptoms expected to change with a treatment, or symptoms which require careful 




Table 1. Demographic characteristics of GIST and breast cancer patients 
 Breast cancer 
Interviews (N=53) 







Patients per country 
N(%) 
    
UK 13 (25%) 5 (100%) 19 (70%) 5 (100%) 
Poland 7 (13%) 0 5 (19%) 0 
Cyprus 15 (28%) 0 3 (11%) 0 
France 13 (25%) 0 0 0 
Greece  5 (9%) 0 0 0 
Gender     
Female 53 (100%) 5 (100%) 13 (48%) 2 (40%) 
               Male 0 0 14 (52%) 3 (60%) 
Age (years)     
               mean (SD) 56.15 (10.66) 50.80 (9.86) 58.4 (15.4) 52.6 (6.4) 
               range 32-82 38-64 20-85 44-62 
Education level     
Less than compulsory 2 (4%) 0 0 0 
Compulsory school 
education 
13 (25%) 3 (60%) 10 (37%) 3 (60%) 
Post compulsory school 
education (college) 
22 (42%) 0 5 (19%) 1 (20%) 
University 16 (30%) 1 (20%) 12 (44%) 1 (20%) 
Unknown 0 1 (20%)   
Employment status     
Full time 12 (23%) 0  5 (19%) 2 (40%) 
Part time 7 (13%) 1 (20%) 4 (15%) 1 (20%) 
Homemaker 8 (15%) 1 (20%) 1 (4%) 0 
Retired 14 (26%) 1 (20%) 15 (56%) 1 (20%) 
Other1 12 (23%) 2 (40%) 2 (7%) 1 (20%) 
Living situation     
Alone 4 (8%) 1 (20%) 2 (7%) 1 (20%) 
Partner 25 (47%) 4 (80%) 16 (59%) 2 (40%) 
Others 24 (45%) 0 9 (33%) 2 (40%) 
1Other employment categories included sick leave, unemployed, and semi-retired   
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Table 2 Clinical characteristics of GIST and breast cancer patients 
















Disease status      
Localised  32 (60%) 0 10 (37%) 2 (40%) 
Metastatic  20 (38%) 5 (100%) 17 (63%) 3 (60%) 
Missing  1 (2%) 0 0 0 
Years since initial 
diagnosis 
     
<5   41 (77%) 3 (60%) 14 (52%) 3 (60%) 
5-10  8 (15%) 0 10 (37%) 2 (40%) 
10-15  3 (6%) 2 (40%) 2 (7%) 0 
>15  1 (2%) 0 1 (4%) 0 
Treatment       
Trastuzumab  45 (85%) 5 (100%)   
Bevacizumab  7 (13%) 1 (20%)   
Trastuzumab and 
Pertuzumab 
 1 (2%) 0   
Imatinib    27 (100%) 5 (100%) 
Sunitinib    9 (33%) 0 
Regorafenib    5 (19%) 0 
Co-morbidities      
None  42 (79%) 5 (100%) 17 (63%) 2 (40%) 
Renal  0 0 0 1 (20%) 
Cardiac  5 (9%) 0 2 (7%) 0 
Respiratory  1 (2%) 0 1 (4%) 0 
Rheumatic  1 (2%) 0 3 (11%) 0 
Diabetes  1 (2%) 0 0 0 




     
0  39 (74%)  3 (60%) 20 (74%) 4 (80%) 
1  13 (24%) 1 (20%) 4 (15%) 1 (20%) 
2  1 (2%)  1 (20%) 2 (7%) 2 (40%) 
Missing  0 0 1 (4%) 0 
1Other co-morbidities include thyroid problems, hypertension, hip replacement, chronic fatigue 





Table 3.  Recruiting country and specialist discipline of the Breast cancer and GIST HCPs* 





HCPs per country N(%) N(%) 
UK 6 (38%) 6 (67%) 
France 4 (25%) 0 
Poland 4 (25%) 0 
Cyprus 0 3 (33%) 
Greece 2 (13%) 0 
Specialist discipline   
Medical / Clinical Oncology 13 (81%) 6 (67%) 
Nursing 3 (19%) 2 (22%) 
Palliative Medicine 0 1 (11%) 
 






Table 4. Number of items across the symptom categories in the draft and final item set, and 
contribution made by each method to the item sets 
Symptom Category Draft  Final  Comment Symptoms not captured by all 
methods 
Skin  8 6 2 redundant items 
(sores/ulcers and sun 
sensitivity) removed 
• Colour change 
(literature and patients 
only); 
• Sores/ulcers (patients 
and HCPs only) 
• Sun sensitivity (patients 
only) 
Swelling  2 2  Captured by all methods 
Musculo-skeletal 4 4  • Bone pain (patients and 
HCPs only) 
• Back pain (literature 
and patients only) 






1 Hair items omitted 
because long term 
changes, and difficult 
to attribute 
Captured by all methods 
Heart and breathing 4 4 Categories combined; 
two items in each 
• Heart palpitations 
(patients only) 
• Chest pain (literature 
and HCPs only) 
Fatigue/energy 3 3  Captured by all methods 
Eyes 7 7  • Dry eyes (patients and 
HCPS only) 
• Itchy eyes (patients and 
HCPS only) 
ENT 4 4  • Changes to voice 
(literature and patients 
only) 
Emotional function 5 5 Combined emotional (3 
items) and cognitive (2 
items) symptoms.  
• Concentration 
(literature and patients 
only) 
• Tense (patients only) 
• Irritability (literature 
and patients only) 
Digestion  13 11 Combined 3 groups: 
bowels, upper 
gastrointestinal tract, 
eating and appetite. 
2 items redundant/not 
relevant including 
restricted diet and 
change in bowel habits 
• Bowel urgency 
(patients and HCPs 
only) 
• Painful bowel 
movements (literature 
and HCPs only) 
• Flatulence (literature 






Musculo-skeletal refers to symptoms affecting the joints, bones and muscles. 












• Indigestion (literature 
and patients only) 
General 15 9 6 items not relevant or 
did not fit time frame 
(weight gain, weight 
loss, infections, 
frequent urination, 
fainting, feeling unwell) 
• Hot flushes (patients 
and HCPs only) 
• Infections (literature 
only) 
• Pale/cold fingers and 
toes (patients only) 
• Tingling/numbness in 
hands or feet 
(literature and patients 
only) 
• Frequent urination 
(patients only) 







Table 5. Symptoms represented in the final item set and reported incidence according to cancer type  
Symptom Category Symptoms CML Breast 
cancer 
GIST 
Skin  Skin colour change 
Itchy skin 
Skin rash 
Dry, flaking or cracked skin 





















Swelling  Swelling of legs and ankles  










Musculo-skeletal Muscle aches, pains or cramps 
Aches or pains in joints 















Mouth Dry mouth 
Taste change 




















Heart and breathing Heart palpitations  
Chest pain 

















Fatigue/ energy Tiredness 
Weakness 














Eyes Watery eyes 
Dry eyes 
Red (bloodshot) eyes 
Itchy eyes 
Burning eyes 


























ENT Nose bleeds 
Other nose problems (smell, sneezing) 
Hearing problems 
















Note. Symptoms are scored according to whether they had been experienced within the past week 
√= present; X = absent 
  

























Digestion  Diarrhoea 
Constipation 
Toilet urgency 















































Tingling or numbness in hands or feet 











































Identified from the 
literature, interviews 
and focus groups 
82 Symptoms 
Clinical review                  
6 Do not fit symptom          
definition                                 
2 Similar in content 
59 Low relevance                      
13 Similar in content           
1 Lacks specificity                    
1 Does not fit symptom 
definition                           
60 Symptoms similar in 
content                               
1 Not TT-related 
Draft Set         
74 Symptoms 
Final Set          
61 Symptoms 
9 Not relevant within 
the time frame (i.e., 
long-term change)              
4 Similar in content          
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